NCT00737438: Pre-operative Chemotherapy Plus Bevacizumab With Early Salvage Therapy Based on PET Assessment of Response in Patients With Locally Advanced But Resectable Gastric and GEJ Adenocarcinoma |
|
|
| Completed | 2 | 22 | US | epirubicin, cisplatin, capecitabine, bevacizumab, docetaxel and irinotecan, Patients who have a poor PET response to cycle 1 of ECX plus bevacizumab, (eg. < 35% FDG reduction on the week 3 PET scan compared with baseline), will be switched to salvage therapy of docetaxel and irinotecan (DI)., This treatment will be administered on week 1 and 2 of a 3, week cycle for 2 cycles. Patients will receive bevacizumab for the 1st cycle, of salvage docetaxel/irinotecan only. There is again a planned 10-12 week time, interval (eg. 70-84 days) between the last bevacizumab treatment and surgery. | Memorial Sloan Kettering Cancer Center, Genentech, Inc., Weill Medical College of Cornell University | Esophageal Cancer, Gastric Cancer | 02/15 | 02/15 | | |
| Completed | 2 | 171 | Europe | Epirubicin, Cisplatin, Capecitabine, Panitumumab, Xeloda®, Epirubicin, Cisplatin, Capecitabine, Vectibix®, Xeloda® | AIO-Studien-gGmbH, Amgen, WiSP Wissenschaftlicher Service Pharma GmbH | Stomach Neoplasms, Gastroesophageal Junction Neoplasms | 08/16 | 08/17 | | |
| Completed | 1b/2 | 130 | US, Canada, Europe, RoW | Capecitabine, Xeloda, Epirubicin, AMG 102, Cisplatin, Placebo | Amgen | Esophagogastric Junction Adenocarcinoma, Gastric Cancer, Esophageal Cancer | 11/10 | 06/13 | | |
